

Article

Genotyping of rs228666 SNP of the human gene ACE2 in mild, moderate and sever Covid-19 patients.

Amer M. Kradi¹, Abdul Hussein M. AlFaisal², Ahmed M. Turki³

¹ Health Ministry-Anbar Hospital-Anbar Health department-Iraq.

²Institute of Genetic Engineering and Biotechnology for postgraduate Studies, University of Baghdad-Baghdad – Iraq.

³Anbar University-College of Science , Anbar , Iraq .

*Correspondence: <mailto:alkradi1975@gmail.com>

Abstract: The *ACE2*-converting enzyme has been identified as the specific receptor for Corona virus, but the effect of the *ACE2* gene polymorphism is still unknown, so the expression of human *ACE2* independently may affect the susceptibility to infection with Covid-19. Corona virus is an infectious and pandemic disease caused by it. To evaluate the association between the *ACE2* gene polymorphism and the severity of Covid-19 infection, we used PCR polymerase reaction and polymorphism methods to examine 80 patients classified into severe infection based on symptoms and 80 control factors.. Results demonstrated statistical significance in this high-risk group and the function of rs228666 SNP in the risk of infection with the independent *ACE2* gene rs228666. Individuals who have the variation A allele may be more vulnerable to infection than those who carry G in a condition with the GA genotype when compared to other genotypes GG, GA, while the AA genotype was not significant. Corona virus susceptibility and disease severity were related to inflammation and genetic polymorphism, while there was no clear evidence linking this rs228666 SNP to the severity of Covid-19 infection. At the 0.01 % probability level, the prediction of the GG genotype for control was not significant. In the case of mild infections, the *ACE2* rs228666 SNP genotype was found to be a protective factor for infection with Covid-19 illness in Iraqi patients. Furthermore, patients with this GA genotype are more likely to develop Covid-19 illness than the other genotypes, although the AA genotype had no significant effect on this disease. Individuals with the A allele are also more likely to be infected with COVID-19 than those with the G allele, according to the findings. The GG genotype of the *ACE2* rs228666 SNP was substantially greater at the 0.01 % probability level in the medium cases compared to the control group, showing that the GG genotype of the *ACE2* rs228666 SNP is a protective factor against the incidence of infection. With Covid-19 in Iraqi patients, however the values of the AA genotype are not significant, implying that an individual who carries the A allele is more likely to get Covid-19 disease than those who possess the GG allele.

Keywords: Coronavirus , SNP , *ACE2*.

1. Introduction

Coronaviruses (CoVs) are enveloped viruses containing positive-sense single-stranded RNA as their genetic material^{1,2}. The phylogenetic analyses of its genome indicated SARS-CoV-2 as a member of the genus *Betacoronavirus*, which also includes SARS-CoV, SARSr-CoV, MERS-CoV and many other viruses

as well reported to have been isolated from humans and other animal species³. Although SARS-CoV-2 shares more than 93.1% sequence similarity of spike (S) gene with of BatCoV RaTG13, the similarity percentage with SARS-CoV and other SARS-CoVs has been exhibited to be lower than⁴ 80%. Paradoxically, although *ACE2* receptor provides the entry point for some coronaviruses into the body, it has been found to play a protective role in several pathophysiological processes too. These include alleviating pathological changes in acute lung injury and acute respiratory distress syndrome⁵, protection against diabetes, hypertension, cardiovascular disease and organ damage as well, by regulation of the renin-angiotensin system (RAS)⁶. The RAS maintains the blood pressure homeostasis in addition to fluids and salts balance which is crucial for the pathological and physiological regulation of several organs including kidney, heart and lungs⁷. *ACE2* primarily functions by negatively regulating the RAS⁸ and via degrading and converting the Angiotensin II (potent in vasoconstriction, pro-fibrosis and pro-inflammation) to Angiotensin 1-7 (vasodilatory, apoptotic and proliferative)⁵.

2. Materials and Methods

The RealLine Extraction 100 kit can be applied in clinical practice during diagnostics of different human infections and diseases by the polymerase chain reaction (PCR) method and by reverse transcription with subsequent polymerase chain reaction (RT-PCR). Extraction of Human DNA from Whole Blood Total genomic DNA isolated from the whole fresh blood have been collected in EDTA containing tubes for molecular studies, was applied using genomic DNA purification kits (The WizPrep™ DNA Extraction Kit).

Primer preparation:

Table (3-9): Sequences of primer *ACE-2* SNP rs 228666.

Name of primers	Sequence of primers	Reference
ACE2 IF	5'- CATAATCACTACTAAAATTAGTATCC -3'	Newly Designed
ACE2 IR	5'- TTATTACTTGAACCAGGGAA -3'	
ACE2 OF	AAGTAAATGTGATACAATTTACAAG	Newly Designed
ACE2 OR	AAAGGATATCTTTATATTAGCATTC	
Product For A allele	159	
Product for G allele	200	
Product for two outer	313	

*IF: Inner Forward

OR: Outer Reverse

Temperatures and time of T-ARMS PCR Programs:

Optimization of PCR reaction was accomplished after several trials for annealing phase (Annealing 51C°). It was then selected temperature of 51C° that give the best results for polymerase chain reactions. Been dealing with other temperatures (denaturation and Extension) without changing the previous research program for PCR (*ACE-2*) gene (thus the following programs were adopted). The PCR reaction was carried out as shown in Table(3-10).

Table (3-10): PCR Programs for *ACE-2* SNP rs 228666 of T-ARMS.

Steps	Temperature (°C)	Time (minutes)	No. of Cycles
Initial denaturation	96	2	1
First loop:			
Denaturation	96	1	30
Annealing	51	1	
Extension	72	1	
Final extension	72	10	1

3.Results and Discussion

The results of genotypes and alleles frequencies of rs2286666 SNP in *ACE2* gene in controls and patients with Covid-19 are presented in Tables 4-1, 4-2, 4-3 and 4-4. The percentage of wild-type GG genotype was non significantly ($p \leq 0.01$) slightly lower in mild Covid-19 patients group than in controls group (87.5% versus 77.5%, respectively) which represent that genotype GG of the *ACE2* rs2286666 a protective factor against the incidence of Covid-19 in Iraqi patients (OR:1.013) (Table 4-1, Figure 4-1). The results also showed that the percentage of heterozygous mutant GA genotype of the SNP was significantly ($p \leq 0.01$) higher in mild Covid-19 patients than in controls (6,25% versus 12%, respectively) which represent that patients with this genotype could be in risk to have Covid-19 disease than other genotypes (OR: 1.4384). While mutant genotype AA result showed a non-significant effect on disease infection. The present results showed that individual with the variant A allele 24 (30%) may have a risk for Covid-19 disease than those carrying G homozygote 136 (70%).

The results of genotypes and allele frequencies of rs228666 SNP of the *ACE 2* gene in controls versus moderate Covid-19 patients represent in Table 4-2, Figure 4-2 and revealed that the wild type GG genotype was significantly ($p \leq 0.01$) high lower in moderate Covid-19 patients group than in controls group (87.5% versus 72.5%, respectively) which indicate again that genotype GG of the *ACE2* rs2286666 is a protective factor against the incidence of Covid-19 in Iraqi patients (OR: 1.037).

On the other hand, heterozygous mutant GA genotype of the SNP was significantly ($p \leq 0.01$) higher in moderate Covid-19 patients than in controls (6,25% versus 18.75%, respectively, OR:3,571) which represent that patients with this genotype could be in risk to have a Covid-19 disease than other genotypes. While mutant genotype AA result was non-significant (6.25% versus 8.75%, respectively) with OR, 0.967. These

results showed that individual with the variant A allele 29 (18%) could be in risk for Covid-19 disease than those carrying G homozygote 131 (82%).

observed⁹ that severely affected COVID-19 infection is related to the virus's expression of *ACE2*, and it was found that the low level of infection with this virus in terms of infection and complications is mild because levels of *ACE2* in the serum are higher in children than in adults, which is the first point of contact, as most epidemiological data showed that the majority of COVID-19 cases in children showed mild or moderate clinical symptoms¹⁰. While the aim is to evaluate the correlation between the genetic polymorphisms of *ACE2*, *ACE1*, and their role in determining the course of the disease (mild, moderate, severe), discovering such a relationship determines the severity or severity of the injury, which somewhat corresponds to what was researched. Concerning the role of this gene in determining the severity of infection in our study, because the number of genetic polymorphisms is very important in determining the severity of infection, as shown¹¹. the expression levels of the *ACE2* gene play a role in the severity of the disease, which corresponds to what was found in Our study is a case of light injuries, and *ACE2* has been linked to injury severity, whether moderate or mild¹². which is consistent with the observations. that moderate¹³ virus is related to the host's immunological response and is not associated with increased expression of *ACE* receptors. It was also found¹⁴ that people infected with mild cases may have diarrhea or show no symptoms at all, which complicates diagnosis and treatment because infected people may be unaware of the infection and spread it. Also¹⁴ discovered that *ACE2* is one of the key receptors for COVID-19 and that the severity of infection is determined by it. when the *ACE2* gene expression is low, the severity of infection is very low, and this decrease prevents the spread of COVID-19. The infection in these cases is moderate and without symptoms, although the World Health Organization (WHO) reports that these cases exhibit disease signs. While it has been demonstrated¹⁵ that only 33% of average cases develop a fever and 67% do not. Elevated plasma *ACE2* levels in COVID-19 have been found to be substantially linked with disease severity, suggesting that *ACE2* production is involved in virus transmission and the burden of disease¹⁶. showed that the *ACE2* protein functions as a receptor for virus entry by establishing a special connection between them, and the expression of the *ACE2* protein varies according to organ¹⁷. It has been discovered¹⁸ that low expression of the *ACE2* protein in the lung is associated with the average condition in the severity of the injury, and all of what has been mentioned gradually agrees with the results obtained despite differences in the type of expression of the *ACE2* protein, whether it is expressed in the lung to accept or reject. Our results were consistent with that of^{18,19} who showed that the lower the *ACE2* expression, the more moderate the injury, especially in the lungs, and when the expression of *ACE2* rose in the lungs, In addition to the fact that pulmonary expression of the *ACE2* gene may contribute to the risk of infection with Covid-19, and as many researchers have proposed, the danger of Covid-19 is tied to *ACE2* and its function in viral infection²⁰.

Table 4-1: Genotype distribution and allele frequency of rs228666 ACE 2 gene in COVID-19 mild infected patients and control group.

Genotype (ACE 2)	Healthy No. (%)	Patients No. (%)	Chi-Square (χ^2)	P-value	O.R. (C.I.)
GG-wild	70 (87.5%)	62 (77.5%)	0.457	0.5001*	1.013
GA	5 (6.25%)	12 (15%)	0.3604	0.5501*	1.4384
AA	5 (6.25%)	6 (7.5%)	0.0976	0.7550 ^{NS}	0.921
Total	80 (100%)	80 (100%)			
Allele	Frequency				
G	145 (90%)	136 (70%)			
A	15 (10%)	24 (30%)			




Figure 4-1 :The 200 bp band indicates the G allele and the 159 bp band indicates the A allele. The 313 bp band indicates the product of the outer primers and was used as positive control for the PCR reactions. Genotype GG homozygote (lanes 1,3,4,5,7,9,10,12,14,15,17,18,20,22,24), genotype GA heterozygote (lanes 6,11,19) and genotype AA homozygote (lanes 2,13,23).

Table 4-2: Genotype distribution and allele frequency of rs228666 ACE 2 gene in COVID-19 Moderate infected patients and control group.

Genotype ACE 2)(Healthy No. (%)	Patients No. (%)	Chi-Square (χ^2)	P-value	O.R. (C.I.)
GG-wild	70 (87.5%)	58 (72.5%)	5.625	0.0203*	1.037
GA	5 (6.25%)	15 (18.75%)	5.714	0.0193**	3.5714
AA	5 (6.25%)	7 (8.75%)	0.3604	0.4023 NS	0.967
Total	80 (100%)	80 (100%)			
Allele	Frequency				

G	145 (90)	131 (82%)		
A	15 (10%)	29 (18%)		
* (P≤0.05), ** (P≤0.01), NS: Non-Significant.				




Figure 4-2 :The 200 bp band indicates the G allele and the 159 bp band indicates the A allele. The 313 bp band indicates the product of the outer primers and was used as positive control for the PCR reactions. Genotype GG homozygote (lanes 1,2,5,6,7,9,10,11,13,14,16,17,18,19,22,23,24,25), genotype GA heterozygote (lanes 8,12,) and genotype AA homozygote (lanes 3,15,20).




Figure 4-4:The 200 bp band indicates the G allele and the 159 bp band indicates the A allele. The 313 bp band indicates the product of the outer primers and was used as positive control for the PCR reactions. Genotype GG homozygote (lanes 1,2,3,4,5,6,7,8,9,10,11,13,14,15,16,17,19,20,21,22,23,24,25), genotype GA heterozygote (lanes 12) and genotype AA homozygote (lanes 18).

The results of genotypes and allele frequencies of rs228666 SNP of the *ACE 2* gene in controls *versus* sever Covid-19 patients represent in Table 4-3, Figure 4-3. The results revealed that the wild type GG genotype was significantly ($p \leq 0.01$) high lower in sever Covid-19 patients group than in controls group (87.5% *versus* 21.25%, respectively, OR:1.01) which confirm that genotype GG of the *ACE2* rs2286666 is a protective factor against the incidence of Covid-19 in Iraqi patients.

The result of heterozygous mutant GA genotype of the SNP was significantly ($p \leq 0.01$) higher in sever Covid-19 patients than in control (6,25% *versus* 70%, respectively, OR:3,571). These result indicated that the severity of patients infected with Covid-19 disease could be due to the genotype of *ACE2* rs2286666 SNP where the severity increased in patients with the genotype GA than other genotypes (GG and GA). On the other hand, mutant genotype AA result was non-significant (6.25% *versus* 8.75%, respectively) with OR, 0.9014. The results also showed that individual with the variant A allele 70 (45%) could be in risk for Covid-19 disease than those carrying G homozygote 90 (55%). Showed²¹ that the virus causes an equilibrium by *Ang 1* in the host cells it targets, which significantly increases lung damage, which is consistent with the

effect on patients in severe cases who suffer from shortness of breath and damage. *ACE2* is a specific receptor for the virus in the lung, although the potential effect of *ACE2* genetic polymorphism is undetermined. Confirmed²² that this gene affects sensitivity to COVID infection and disease outcome, but there was no effect on infection severity, stating that there is no evidence that the *ACE2* and *ACE1* polymorphisms are directly related to disease severity. linked²³ the severity of infection to differences in individuals based on epigenetic alleles of gene expression of the *ACE2* receptor, which is completely consistent with the observations. While⁹ found that the increased susceptibility to Covid-19 infection is related to the expression of the targeted *ACE2* receptor, our results in terms of age in infection with the virus and the role of *ACE2* enzyme coincide with²⁴ Unlike most other studies that evaluated the relationship between gender and the severity of infection, we did not use gender as an indicator of infection in our current study. These studies concluded that gender really wasn't significantly related to the risk of disease spread, whereas other studies found that men were more susceptible to this disease and more severely²⁵ and in contrast to what we found, mentioned²⁶ a negative relationship between *ACE2* and *ACE1* in the severity of infection and mortality, whilst also²⁷ identified a highly high expression of *ACE2* protein in postmortem lung tissues from Covid-19 patients. What stands out here is the function of the *ACE2* protein in generating infection and infection with COVID 19, as well as patient death. This is consistent with what we discovered about this protein throughout our study.

Table 4-3: Genotype distribution and allele frequency of rs228666 *ACE 2* gene in COVID-19 sever infected patients and control group.

Genotype ACE 2)(Healthy No. (%)	Patients No. (%)	Chi-Sq uare (χ^2)	P-value	O.R. (C.I.)
GG-wild	70 (87.5%)	17 (21.25%)	70.77	0.0001 **	1.01
GA	5 (6.25%)	56 (70%)	64.47	0.0001 **	11.247
AA	5 (6.25%)	7 (8.75%)	1.252	0.2694 NS	0.9014
Total	80 (100%)	80 (100%)			
Allele	Frequency				
G	145 (90%)	90 (55%)			
A	15 (10%)	70 (45%)			
* (P≤0.05), ** (P≤0.01), NS: Non-Significant.					




Figure 4-3:The 200 bp band indicates the G allele and the 159 bp band indicates the A allele. The 313 bp band indicates the product of the outer primers and was used as positive control for the PCR reactions.

Genotype GG homozygote (lanes 1,3,4,5,7,8,10,12,14,15,17,18,20,22,24), genotype GA heterozygote (lanes 6,8,11,16,19,21,25) and genotype AA homozygote (lanes 2,13,23).

4. Conclusions

Genotype GG of the *ACE2* rs228666 is a protective factor against the incidence of Covid-19 in Iraqi patients. Heterozygous mutant GA genotype of the SNP *ACE2* rs228666 could be play a role in risk to have a Covid-19 disease than other genotypes.

5. References:

- Lai, M. Coronaviridae. *Fields Virology, I*, **2007**;1305–1318.
- Lu, G.; Liu, D. SARS-like virus in the Middle East A truly bat-related coronavirus causing human diseases. *Protein & Cell*,**2012**; 3(11), 803–805.
- Wu, F.; Zhao, S.; Yu, B.; Chen, Y.M.; Wang, W.; Song, Z.G.; Hu, Y.; Tao, Z.W.; Tian, J.H.; Pei, Y.Y.; Yuan, M.L.; Zhang, Y.L.; Dai, F.H.; Liu, Y.; Wang, Q.M.; Zheng, J.J.; Xu, L.; Holmes, E.C.; Zhang, Y.Z. A new coronavirus associated with human respiratory disease in China. *Nature*, **2020**; 579(7798), 265–269.
- Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; Chen, H.D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.D.; Liu, M.Q.; Chen, Y.; Shen, X.R.; Wang, X. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*, **2020**; 579(7798), 270–273.
- Hamming, I.; Cooper, M.E.; Haagmans, B.L.; Hooper, N.M.; Korstanje, R.; Osterhaus, A.D.; Timens, W.; Turner, A.; Navis, G.; van Goor, H. The emerging role of ACE2 in physiology and disease. *The Journal of Pathology*,**2007**; 212(1), 1–11.
- Cheng, H.Y.; Li, S.Y.; Yang, C.H. Initial rapid and proctive response for the COVID-9 outbreak Taiwns experience. *J Formos Med Assoc.* **2020**; 119(4): 771-773.
- Patel, S.; Rauf, A.; Khan, H.; Abu-Izneid, T. Renin-angiotensin-aldosterone (RAAS):The ubiquitous system for homeostasisandpathologies. *Biomedicine&Pharmacotherapy = Biomedecine & Pharmacotherapie*,**2017**; 94, 317–325.
- Kuba, K.; Imai, Y.; Ohto-Nakanishi, T.; Penninger, J.M. Trilogy of ACE2: A peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. *Pharmacology & Therapeutics*,**2010**; 128(1), 119–128.

9. Wan, Y.; Shang, J.; Graham, R.; Baric, R.S.; Li, F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. *J Virol.* **2020**;94:e00127-20.
10. Bunyavanich, S.; Do, A.; Vicencio, A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. *JAMA.* **2020**;323:2427-2429.
11. Perlman, S.; Netland, J. Coronaviruses post-SARS: update on replication and pathogenesis. *Nat Rev Microbiol.* **2009**;7:439–450. doi: 10.1038/nrmicro2147.
12. Saponaro, F.; Rutigliano, G.; Sestito, S. et al. ACE2 in the era of SARS-CoV-2: controversies and novel perspectives. *Front Mol Biosci.* **2020**;7:588618.
13. M. Ajeel, A.; A. Mehdi, L. . Effect Of Eruca Sativa Seeds Powder As Feed Supplementation On Some Physiological Traits Of Male Lambs. *Journal of Life Science and Applied Research.* **2020**, 1, 20-30.
14. Chai, X.; Hu, L.; Zhang, Y.; Han, W.; Lu, Z.Ke. A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. *bioRxiv.* **2020**;02.03.931766. doi: 10.1101/2020.02.03.931766.
15. Emad H. H. Alsalmany , TH. T. Mohammed. Effect of adding natural zeolite and vitamin E to diets of laying hens (Lohman Brown) on some physiological traits and productive performance during hot weather. *Revis Bionatura .2022*;7(4) 12. <http://dx.doi.org/10.21931/RB/2022.07.04.12>.
16. Hou, Y.J. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. **2020**; *Cell* 182, 429-446.e14.
17. Damiani, S. Pathological post-mortem findings in lungs infected with SARS-CoV-2. *J. Pathol.* **2021**; 253, 31–40.
18. Pathangey, G.; Fadadu, P.P.; Hospodar, A.R.; Abbas, A.E. Angiotensin-converting enzyme 2 and COVID-19: Patients, comorbidities, and therapies. *Am. J. Physiol.* **2021**; *Cell. Mol. Physiol.* 320, L301–L330.
19. Medina-Enríquez, M.M. ACE2: The molecular doorway to SARS-CoV-2. *Cell Biosci.* **2020**; 10, 148.
20. Alghamri, M.S.; Weir, N.M.; Anstadt, M P.; Elased, K.M.; Gurley, S.B.; Morris, M. Enhanced Angiotensin II-Induced Cardiac and Aortic Remodeling in ACE2 Knockout Mice. *J. Cardiovasc.Pharmacol.Ther.* **2013**; 18, 138–151. doi:10.1177/1074248412460124.
21. Li, Y. Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-κB signaling pathways. *Sci Rep.* **2016**;6(1):1–14.
22. Sevim, KarakaşÇelik GüneşÇakmak Genç, NihalPişkin, BilgehanAçikgöz, BülentAltınsoy , BaşakKurucuİşsiz, and AhmetDursun Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: A case study *J Med Virol.* **2021**; Oct; 93(10): 5947–5952. Published online Jul 10. doi: 10.1002/jmv.27160
23. Hatami, N.; Ahi, S.; Sadeghinikoo, A. Worldwide ACE (I/D) polymorphism may affect COVID-19 recovery rate: an ecological meta-regression. *Endocrine.* **2020**;68:479-484.
24. Williamson, E.J.; Walker, A.J.; Bhaskaran, K. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. *Nature* **2020**;584:430–436.
25. Gómez, J. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. *Gene.* **2020**;762:145102.
26. Delanghe, J.R.; Speeckaert, M.M.; De-Buyzere, M.L. The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. *Clin Chim Acta.* **2020**;505:192-193.

27. Atish, Gheware, Animesh Ray, DeekshaRana, PrashantBajpai, ArunaNambirajan, S. Arulsevi, PurvaMathur, AnjanTrika, SudheerArava, Prasenjit Das, *Scientific Reports* volume, **2022**; 12, Article number: 4058 [Cite this article](#) ACE2 protein expression in lung tissues of severe COVID-19 infection.